Novo Nordisk has taken legal action against Eli Lilly, escalating the competition between two of the world’s leading pharmaceutical companies in the rapidly expanding GLP-1 obesity and diabetes treatment market.
On July 21, 2026, Novo Nordisk announced that it filed a lawsuit against Eli Lilly and Lilly USA in the U.S. District Court for the District of New Jersey, alleging that Lilly’s national advertising campaigns for Zepbound® (tirzepatide) and Mounjaro® (tirzepatide) create a misleading impression about treatment superiority.
The lawsuit claims that Lilly’s direct-to-consumer advertisements use outdated clinical comparisons while excluding important scientific evidence about newer, higher-dose options available for Novo Nordisk’s medicines, including Wegovy® (semaglutide) and Ozempic® (semaglutide).
According to Novo Nordisk, the advertisements compare Lilly’s highest approved injectable doses with lower doses of Novo Nordisk’s therapies, potentially causing consumers to believe that Lilly’s medicines provide better outcomes across all treatment options.
One of the major concerns raised in the lawsuit involves the comparison between Zepbound® and Wegovy®. Novo Nordisk stated that Lilly’s campaigns rely on studies comparing Zepbound’s 10 mg and 15 mg doses with Wegovy’s earlier 1.7 mg and 2.4 mg doses.
The company argues that these advertisements fail to include data from the FDA-approved 7.2 mg dose of Wegovy®, which demonstrated an average body weight reduction of approximately 19%, equivalent to around 47 pounds in clinical studies.
Novo Nordisk further stated that there is currently no head-to-head clinical trial comparing the highest doses of Zepbound and Wegovy®, making broad claims of product superiority potentially inaccurate.
The company also challenged Lilly’s advertising comparing Mounjaro® with Ozempic®. Novo Nordisk claims Lilly’s campaigns compare its 15 mg Mounjaro dose against a lower 1 mg dose of Ozempic®, while excluding the FDA-approved 2 mg maintenance dose.
The dispute highlights the growing importance of accurate scientific communication as GLP-1 therapies become increasingly popular among patients seeking obesity and type 2 diabetes treatments.
Novo Nordisk stated that millions of Americans rely on advertising and public health information when considering treatment options, making updated and complete clinical information essential for informed healthcare decisions.
The lawsuit follows a previous cease-and-desist request from Novo Nordisk, which the company said Lilly declined to fully address. Novo Nordisk is now seeking legal action to stop the advertisements and require corrective communication across platforms.
The company is requesting a permanent injunction requiring Lilly to remove what it describes as misleading comparative advertisements and launch corrective advertising to provide consumers with accurate treatment information.
The legal battle represents another major development in the competitive GLP-1 drug sector, where pharmaceutical companies are investing heavily in obesity, diabetes, and metabolic disease treatments.
Both Novo Nordisk and Eli Lilly have experienced significant growth from their GLP-1 portfolios, with products such as Wegovy®, Ozempic®, Zepbound®, and Mounjaro® becoming some of the most closely watched therapies in the global pharmaceutical industry.
As demand for weight management and diabetes medicines continues to rise, competition between manufacturers is expanding beyond clinical performance into areas such as marketing, consumer education, pricing, and market positioning.
About Author
Payal Rabde is a Healthcare Market Research Analyst with over 4 years of experience in pharmaceutical, biotechnology, medical device, and healthcare market research. She holds an MBA in Pharmaceutical-Biotechnology Management and a B.Pharm, specializing in market analysis, forecasting, competitive intelligence, and strategic healthcare insights.
About Novo Nordisk
Novo Nordisk is a Denmark-based global healthcare company specializing in diabetes care, obesity treatment, rare blood disorders, and other chronic disease therapies.
Founded more than 100 years ago, the company has built a strong reputation in metabolic healthcare through innovative medicines, including GLP-1 therapies such as Ozempic® and Wegovy®.
Novo Nordisk continues to invest in research and development focused on improving treatments for obesity, diabetes, and other serious chronic conditions while expanding access to advanced healthcare solutions worldwide.
Resources:
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916584
https://www.towardshealthcare.com/insights/diabetes-drugs-market
https://www.towardshealthcare.com/insights/diabetes-medicines-market-sizing